Prescription drug · BLA
Wezlana (ustekinumab-auub) NDC 84612-066
Ustekinumab 130 mg/26mL · Injection, Solution · Intravenous · Nuvaila Limited
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 84612-066-01 | 84612006601 | 1 VIAL in 1 CARTON (84612-066-01) / 26 mL in 1 VIALMarketed from Jan 1, 2025 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Wezlana
- Generic name (nonproprietary)
- ustekinumab-auub
- Active ingredients
- Ustekinumab — 130 mg/26mL
- Dosage form
- Injection, Solution
- Route
- Intravenous
- Labeler
- Nuvaila Limited
- Product type
- Prescription drug
- Marketing category
- BLA — Biologics License ApplicationApplication BLA 761331
- Marketing start
- Listing expires
- Other FDA classes
- Interleukin-12 Antagonists (Mechanism)Interleukin-23 Antagonists (Mechanism)
- Identifiers
- Product ID 84612-066_4feadcb0-90b7-4e84-90c2-2eaaa8868ca8SPL ID 4feadcb0-90b7-4e84-90c2-2eaaa8868ca8SPL set ID a6c23978-09f0-4796-88f7-d0ce7e3ed04eRxCUI 2700669, 2700676, 2700679, 2700682, 2700685, 2700689, 2700691, 2700692UNII FU77B4U5Z0
- Pharmacologic class
- Interleukin-12 Antagonist; Interleukin-23 Antagonist
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N484612006601followed by a unit qualifier and the quantityPackage 84612-0066-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
WEZLANA is a human interleukin -12 and -23 antagonist indicated for the treatment of: Moderate to severe plaque psoriasis in adult and pediatric patients 6 years of age and older who are candidates for phototherapy or systemic therapy. ( 1.1 ) Active psoriatic arthritis in adult and pediatric patients 6 years of age and older. ( 1.2 ) Moderately to severely active Crohn's disease in adult patients. ( 1.3 ) Moderately to severely active ulcerative colitis in adult patients . ( 1.4 ) 1.1 Plaque Psoriasis (PsO) WEZLANA is indicated for the treatment of adults and pediatric patients 6 years of age and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic …
Excerpt only. Read the full label for complete information.